Friday, 29 March 2024


GE Healthcare, Germfree advance manufacturing of novel biotherapeutics

13 September 2019 | News

The collaboration with Germfree represents a significant contribution to increase capacity and capability in the gene therapy market

GE Healthcare and Germfree are joining expertise to develop a fully integrated, expandable manufacturing solution for emerging biotherapeutics, including gene therapy.

Current market indicators predict a compound annual growth rate of more than 36% in the cell and gene therapy market during 2019-2025. With more than 700 cell and gene therapies currently in clinical trials, demand exceeds supply. The collaboration with Germfree represents a significant contribution to increase capacity and capability in the gene therapy market.

The manufacturing solution will feature a Germfree modular bioprocessing environment based on GE Healthcare's proprietary design and equipped with FlexFactory™, GE Healthcare's integrated single-use biomanufacturing platform. This will be the latest addition to GE Healthcare's KUBio™ prefabricated manufacturing facility offering.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account